NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate in patients with platinum-resistant high grade serous ovarian carcinoma.

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Jalid Sehouli, Toon Van Gorp, Elena Ioana Braicu, Shiraj Sen, Valentina Boni, Rebecca Sophie Kristeleit, Ignacio Garcia Matos, Sebastien Ochsenreither, Debra L. Richardson, Alexander Spira, Alexander Starodub, Juergen Wolf
+6 more Katrien de Graaf, Björn M Hock, Guenter Fingerle-Rowson, Yariv J. Houvras, Ines Isabel Monteiro Vasconcelos, Antonio González-Martı́n
DOI: 10.1016/j.ijgc.2025.103078
Cited by: 0

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment Monoclonal and Polyclonal Antibodies Research Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103078–103078
Publication date
1 February 2026
Language
EN